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pegvisomant (13%) and bromocriptine (7%). Baseline co-morbidities (CM) included
hypertension (66%), carpal tunnel syndrome (23%), osteoporosis (16%), dyslipide-
mia (12%), visual disturbance (12%), sleep apnea (2%), myocardial infarction (2%)
and renal calculi (2%). Distribution of co-morbidities was statistically significantly
higher than general population (p-value 0.05); specifically those with 1 CM (41%)
or 3 CM (19%) or more. Longitudinal assessment of co-morbidities reported no
statistically significant difference prior and post therapy. CONCLUSIONS: This ret-
rospective analysis of patients diagnosed with acromegaly indicates that they re-
quire substantially higher resource use and experience a high burden of comor-
bidities.
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OBJECTIVES: An important factor to take into account when evaluating the effec-
tiveness of a drug is adherence. Adherence describes the degree to which a patient
correctly follows medical advice. The objective of this study was to evaluate the
factors that determine adherence of adult patients with type 2 diabetes treated
with once-daily injectable liraglutide 1.8mg or twice-daily injectable exenatide
10g.METHODS:A retrospective study was conducted employing US data from the
IMS PharMetrics claims database. The index period ranged from January 2010 to
December 2010 and patients needed to be continuously enrolled 12 months before
and after the index date. Patients were treatment naïve to liraglutide and exenatide
but may not have been injection-naïve as prior insulin use was not part of the
patient selection exclusion criteria, which may have impacted the outcomes as a
limitation of the study. Adherence was measured by continuous Medication Pos-
session Ratio (MPR) as well as a categorical response using MPR (MPR80%high
adherence and MPR80%low adherence). The determinants of adherence were
estimated using multivariable models and bivariate testing was conducted for se-
lection of the possible predictors. Covariates were then included and a stepwise
model-building approach was used. RESULTS: Data from 3623 patients (2036 lira-
glutide 1.8mg and 1587 exenatide 10g) were used in the analyses. When adjusting
for confounding effects, patients treated with exenatide 10g were approximately
11% (p.0001) less adherent than patients treated with liraglutide 1.8mg assessed
by the continuous MPR measure. The odds ratio (OR) for achieving a high categor-
ical MPR for liraglutide 1.8mg compared to exenatide 10g was 1.33 in favor of
liraglutide 1.8mg (p.0001). Variables found to impact the level of adherence were
age, gender, the geographic region, treatment, and percentage co-payment from
the claimant. CONCLUSIONS: The analysis showed that once-daily liraglutide
1.8mg is associated with better adherence than twice-daily exenatide 10g.
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OBJECTIVES: To assess the differences in the compliance of Greek patients suffer-
ing from Type 2 diabetes mellitus who receive free combination therapy of met-
formin and vildagliptin compared to the diabetic patients who receive fixed com-
bination therapy of metformin/vildagliptin. METHODS: Eight hundred adult
patients inadequately controlled on twice daily 850mg metformin monotherapy
who were recently added vildagliptin treatment as add on to metformin (fixed dose
combination or free combination) were enrolled in the study. The observation
period was 6 months. Upon treatment initiation each patient received a diary, in
which they had to record their treatment on a daily basis. The diary then was
returned to the physician at the final visit. Additionally, at baseline and at the last
visit of the study, patients were asked to complete a questionnaire related to their
compliance of their indicated treatment. Patients were defined as compliant when
they hadn’t missed any drug dose, received the correct dosage of the medication
and did not interrupt their treatment.RESULTS:The preliminary results the overall
study sample 63% were considered to be compliant. In the between groups analy-
sis, it was found that 56% of patients receiving free combination were compliant
with their treatment compared to a substantially higher 68% of compliant patients
in the fixed combination group (p0,005). Odds Ratio was equal to 1,647, suggesting
that patients receiving free combination were 1.647 times more likely not to com-
ply with their treatment than the patients on fixed combination. A statistically
significant reduction in Hb1Ac was observed in both groups between the first and
last visit (p0,001) but not any difference between two groups, which is attributed
to the short follow-up period. CONCLUSIONS: Patients on fixed dose combination
treatment for Type II Diabetes are more compliant than patients on free dose
combinations. Improved compliance has been shown to improve disease manage-
ment, which can prevent expensive complications.
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OBJECTIVES: Cost-utility analysis of type 2 diabetes mellitus (T2DM) interventions
requires the estimation of utility values. To increase the robustness of such esti-
mates in line with the National Institute for Health and Clinical Excellence (NICE)
requirements a systematic literature review of utility values associated with
T2DM-related complications was performed. METHODS: The review was per-
formed according to NICE methodology recommendations using Medline, Embase,
EconLIT and the NHS Economic Evaluation Database in May 2012. Health utilities
selected were based on the NICE reference case, including a preference for EQ-5D
data and UK population. Landmark study articles reporting multiple utility values
were favoured. RESULTS: A total of 16,578 records were identified. 61 full text
articles were included in the qualitative synthesis. T2DM without complication
values ranged from 0.690 to 0.970. The proposed utility set primarily consisted of
utility values extracted from Clarke 2002 (T2DM without complication: 0.785, myo-
cardial infarction:-0.055, angina:-0.090, heart failure: -0.108, stroke: -0.164, severe
vision loss: -0.074, amputation: -0.28) and Bagust 2005 (peripheral vascular disease:
-0.061, protenuria: -0.048, neuropathy: -0.084, foot ulcer: -0.170 and overweight:
-0.0061 per BMI unit above 25 kg/m2). These values were supplemented by Was-
serfallen 2004 (haemodialysis: 0.621, peritoneal dialysis: 0.581); Kiberd and Jidal
1995 (renal transplant: 0.762); Fenwick (mild non-proliferative diabetic retinopathy
or macular oedema: 0.760, vision threatening diabetic retinopathy: 0.730) as well as
Currie 2006 (major hypoglycaemia: -0.270, minor hypoglycaemia: -0.070). Limita-
tions included the partial lack of studies in a diabetic- or UK-specific population,
the variability in reporting media, mean or values adjusted for confounding factors.
CONCLUSIONS: This set of values should improve the robustness of T2DM modelling
outcomes in line with NICE requirements. Future research could focus on eliciting a
coherent set of values for T2DM-related complications in line with the NICE reference
case and to define the variance around the utility value point estimates.
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OBJECTIVES: To examine the reliability and validity of the Injection Pen Assess-
ment Questionnaire (IPAQ) in a European population. METHODS: The IPAQ is a
29-item measure of objective and comparative ease of use and preference for re-
combinant human growth hormone (rhGH) injection devices based on content
elicited from focus groups and one-on-one interviews of device users. The IPAQ
was included in a Phase 3, open-label, multicenter trial in 136 experienced rhGH
subjects (parent-child dyads) in the United States to test the ease of use and pref-
erence for a new Genotropin® disposable pen (NCT00965484). IPAQ content was
adapted for use in adults and translated into seven languages. Data from a Phase 3,
open-label, multicenter, crossover study (NCT01112865; N120) was used to eval-
uate the psychometric properties of the IPAQ in a mixed sample of dyadic pairs,
adult subjects and caregivers of pediatric subjects. Analyses were conducted by
group and total sample. RESULTS: Confirmatory factor analysis provided evidence
for a second order factor solution for four subscales and a total IPAQ score; and
supported the conceptual framework developed from previous qualitative and
quantitative research. Although IPAQ subscales did not consistently meet accept-
able internal consistency reliability for some group level comparisons, the total
IPAQ score showed high internal consistency for both pens (Cronbach’s alpha 
0.77 – 0.86). In general, the construct validation (predictive validity) findings were
consistent across pens and across subject groups and generally consistent with
those from the US trial. CONCLUSIONS: The IPAQ total score for ease of use dem-
onstrated good internal consistency reliability and good construct validity in mea-
suring ease of use with injection pens to administer rhGH. Findings from this
research are consistent with those from the US-based study, supporting the use-
fulness of the IPAQ total score in evaluating ease of use and preference for injection
pens in clinical trials and in practice.
PDB56
DEVELOPMENT AND VALIDATION OF PATIENT REPORTED ENDPOINTS FOR
T2DM
Bron M1, Hudgens S2, Stokes J2, Banderas B2, Viswanathan P1, Dabbous O1
1Takeda Pharmaceuticals, Deerfield, IL, USA, 2Adelphi Values, Boston, MA, USA
OBJECTIVES: There are no existing patient reported outcome (PRO) measures in
Type 2 Diabetes Mellitus (T2DM) developed in accordance with FDA Guidance on
PROs. The objective of this study was to develop and validate a T2DM-specific PRO
measure examining hypoglycemic symptoms (HS), weight neutrality (WN), medi-
cation tolerability (MT), and medication compliance (MC). METHODS: The Diabe-
tes-Management and Impact Questionnaire (D-MIQ) and the Diabetes-Assessment
of Blood Sugar Questionnaire (D-ABS) were developed in three phases: concept
elicitation (CE; n20), item generation, and cognitive interviews (CIs; n20). The
D-ABS was finalized as a 36-item PRO assessing HS with a yes/no response scale
measuring symptom frequency and an 11-point numeric response scale measuring
symptom severity. The D-MIQ was finalized as an 18-item PRO measuring impacts
of HS, WN, MT, and MC, with four- and five-point Likert-type response scales and a
yes/no scale. Following content validation, a stand-alone observational study was
conducted in 100 subjects to assess the psychometric properties of the D-MIQ and
D-ABS. RESULTS: Subjects had a mean age of 57.4 (SD 12.6) years (52% female, 60%
white). All items on the D-ABS and D-MIQ showed good convergent validity with
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